Stockreport

First Data On Combination Of Enlivex’s Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference

Enlivex Therapeutics Ltd. - Ordinary Shares  (ENLV) 
PDF Nes-Ziona, Israel, Sept. 23, 2019 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced the first prese [Read more]